Jeito
  • About
  • The team
  • Our portfolio
  • ESG & Impact
  • Newsroom
  • Contact
  • English
    • Français
    • English
Select Page

EyeBio Announces Positive Visual, Anatomic and Safety Data from First-in-Human Ph1b/2a AMARONE Trial of Restoret at Macula Society Annual Meeting

by Manon FRACHON | 19 Feb Mon | English

Twelve week data from the Ph1b/2a AMARONE trial reveals Restoret to be well-tolerated in patients with diabetic macular edema and neovascular age-related macular degeneration.  Proof of concept established with strong visual and anatomic outcomes. Treatment-naïve DME...

Jeito Capital participates in a $95 Million financing for HI-Bio™, a US-based clinical-stage biopharma company developing targeted therapies for patients with severe immune-mediated diseases

by Manon FRACHON | 4 Jan Thu | English

One year after its first investment, this new significant participation in HI-Bio™’s Series B financing, alongside major international investors, demonstrates the value creation already achieved by the company and underlines its attractiveness With this 6th...

Jeito Capital portfolio company Advesya emerges from stealth mode with the potential to become a leader in the treatment of hematological malignancies and other tumor treatments

by Manon FRACHON | 3 Jan Wed | English

Paris, France, 3 January 2024 – Jeito Capital (“Jeito”), a global leading independent private equity fund dedicated to biopharma, is pleased to announce the un-stealthing [1] of its portfolio company Advesya, a pioneering biopharma company for...

Jeito Capital announces appointment of new Partner Investor Ksenija Pavletic

by Manon FRACHON | 3 Jan Wed | English

Paris, France, 3 January 2024 – Jeito Capital (“Jeito”), a global leading independent private equity fund dedicated to biopharma, is pleased to announce the promotion of Ksenija Pavletic to Partner Investor. As part of the Jeito founding team with...

Jeito Capital creates a community of leading international Special Advisors to complement its extensive sets of skills and further extend its support to portfolio companies

by Manon FRACHON | 29 Nov Wed | English

Paris, France, November 29th 2023 – Jeito Capital (“Jeito”), a leading global investment company dedicated to biopharmaceuticals in Europe, is proud to announce the formation of its Special Advisors community composed of leading academic and industry experts...
« Older Entries
Next Entries »

Recent Posts

  • Jeito Capital co-leads the oversubscribed €78 million financing in Augustine Therapeutics to develop novel therapies for neuromuscular, cardio-metabolic and neurodegenerative diseases
  • Jeito Capital announces significant participation in $187 million Series A financing for Callio Therapeutics to advance innovative multi-payload ADC programs designed to maximize therapeutic benefit for cancer patients
  • Jeito Capital leads $67.5 million (€64.4 million) Series B financing in XyloCor Therapeutics to develop Novel Gene Therapy in Cardiovascular Disease
  • Jeito Capital announces significant participation in upsized $207.5 million Series C financing in Aviceda Therapeutics to advance Lead Program AVD-104 for Geographic Atrophy into Pivotal Trials
  • Dr Rafaèle Tordjman Receives L’Agefi’s Prestigious 2024 ‘AM Leader’ Award

Recent Comments

    Mentions et autres liens
    We use cookies on our website to provide you with the most relevant experience by remembering your preferences and repeat visits.
    By clicking on "Accept All", you consent to the use of ALL cookies. However, you can visit "Cookie Settings" to provide controlled consent.
    Cookie settingsAccept all
    Manage consent

    Privacy Overview

    This website uses cookies to enhance your experience when browsing the site. Of these, cookies that are categorized as necessary are stored on your browser because they are essential for the basic functionality of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will only be stored in your browser with your consent. You also have the ability to decline these cookies. But disabling some of these cookies may affect your browsing experience.
    SAVE & ACCEPT